https://doi.org/10.5812/jjnpp-146826

The Effect of Chamomile on Moderate Postpartum Depression: A Randomized Controlled Trial in Dezful, Iran

authors:

avatar Maryam Eradi 1 , avatar Parvin Abedi ORCID 2 , * , avatar Somayeh Ansari 2 , avatar Maryam Dastoorpour ORCID 3 , avatar Fereshteh Golfakhrabadi ORCID 4 , avatar Ahmad Fakhri ORCID 5

Department of Midwifery , Reproductive Health Promotion Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Department of Midwifery , Menopause Andropause Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Department of Biostatistics and Epidemiology, Social Determinants of Health Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Department of Pharmacognosy , Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Department of Psychiatry, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Jundishapur Journal of Natural Pharmaceutical Products: Vol.19, issue 3; e146826
published online: June 23, 2024
article type: Research Article
received: March 9, 2024
revised: April 18, 2024
accepted: April 24, 2024

How To Cite Eradi M, Abedi P, Ansari S, Dastoorpour M, Golfakhrabadi F, et al. The Effect of Chamomile on Moderate Postpartum Depression: A Randomized Controlled Trial in Dezful, Iran. Jundishapur J Nat Pharm Prod. 2024;19(3):e146826. https://doi.org/10.5812/jjnpp-146826.

Abstract

Background:

Postpartum depression (PPD) is a disorder that can negatively affect both maternal and neonatal health.

Objectives:

This study aimed to evaluate the effect of chamomile on PPD.

Methods:

This randomized controlled trial was conducted on 144 women with PPD. The women were randomly assigned to an intervention group (n = 72) that received chamomile capsules (500 mg twice a day) and a placebo group that received a placebo for eight weeks. A demographic questionnaire and Beck's Depression Inventory were used to collect the data. The chi-square test, independent t-test, Mann-Whitney U test, and Wilcoxon test were used to analyze the data.

Results:

A total of 128 women completed the study. The mean depression score in the intervention group decreased from 21.66 ± 4.01 at baseline to 18 ± 3.66 after the intervention. In the control group, the depression scores reduced from 22.36 ± 3.83 to 20.09 ± 3.77. The reduction in depression scores was statistically significant in the intervention group compared to the control group (P = 0.002). Before the intervention, 41 (65.1%) women in the intervention group and 50 (76.9%) in the control group had moderate depression. After the intervention, however, 7 (11.1%) women in the intervention group were without depression, and 60.3% had mild depression, while the reduction in the control group was negligible (P = 0.002).

Conclusions:

Chamomile capsules (500 mg) taken twice a day for eight weeks significantly reduced the score and frequency of mild and moderate PPD. However, due to the lack of laboratory evaluation, the results of this study should be interpreted with caution. Further studies are needed to confirm these findings.

1. Background

Postpartum depression (PPD) refers to the depressive mood experienced after childbirth. It includes, but is not limited to, feelings of extreme sadness, anxiety, decreased energy, sleep disturbances, and changes in appetite (1). The global prevalence of PPD is 13.9%, having increased from 9.4% in 2010 to 19.3% in 2021 (2). The prevalence of PPD in Iran is also on the rise. A 2019 study showed that 38.8% of Iranian women experienced PPD (3), while another study indicated that during the COVID-19 pandemic, this rate rose to 68.2% (4). Postpartum depression can negatively affect the physical and psychological health of the mother, her marital relationship, and increase risky behaviors such as suicide, which can endanger the lives of both the mother and her baby (5). Some consequences of PPD for the neonate and infant include impaired mother-infant interaction, impaired cognitive development, and reduced exclusive breastfeeding (6).

Antidepressant medications are recommended for severe PPD. However, these medications are usually associated with side effects such as nausea, vomiting, sleepiness, lightheadedness, hypertension, dissociation, increased heart rate, and visual changes (7). Non-pharmacological treatments recommended for PPD include talk therapy, cognitive behavioral therapy, and mindfulness-based interventions (8). Herbal medicines such as lavender and aromatherapy, with or without massage, have also shown beneficial effects on PPD (9).

Chamomile is a traditional medicine containing terpenoids and flavonoids that can be effective in treating inflammation, muscle spasms, insomnia, and rheumatic pain (10). Amsterdam et al. reported that chamomile has anti-anxiety and antidepressant effects, finding it effective in participants with generalized anxiety disorder (11). Additionally, a study by Chang and Chen found that chamomile tea could significantly reduce scores of sleep insufficiency and depression, though these effects were limited to immediate use and did not last after four weeks of intervention (12). Another study showed that chamomile tea could significantly reduce anxiety and depression levels in postmenopausal women (13). Chamomile's anti-inflammatory, antioxidant, anti-allergic, and antimicrobial activities have also been reported in other studies (14-17). Despite previous studies showing the effect of chamomile on anxiety and depression among various participants, evidence about its impact on postpartum women is rare.

2. Objectives

Therefore, the present study aimed to evaluate the effect of taking chamomile capsules on the improvement of PPD in Iran.

3. Methods

This randomized controlled trial was conducted with the participation of 144 women who had PPD. The study design was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences (ref No: IR.AJUMS.REC.1400.523), and the protocol was registered in the Iranian Registry for Randomized Controlled Trials (ref No: IRCT20211207053313N1). All women provided written informed consent before data collection. Data collection started in March and was completed in July 2023.

3.1. Sample Size

Considering a previous study (12) and using the following formula, the sample size was calculated to be 65 for each group, intervention and control. Adding 10% to account for the attrition rate, the final sample size was determined to be 72 in each group.

n=s12+s22(z1-α2+z1-β)2(x¯1-x¯2)2=4.1542+4.3612(1.96+1.04)2(9.51-7.26)2=65

Control-group mean (¯x1) = 9.51

Experimental group mean (¯x2) = 7.26

Control group standard deviation (s1) = 4.154

Experimental group standard deviation (s2) = 4.361

Significance level (α) = 0.05

Power of study (1-β) = 0.85

z 1-α/2= 1.96

z 1-β = 1.04

3.2. Inclusion/Exclusion Criteria

Women were eligible to participate in the study if they met the following criteria: They were between two weeks to six months postpartum, had moderate or mild PPD, were of reproductive age (18 - 45 years), had basic literacy, and had given birth to a singleton, living baby. Women suffering from liver or kidney disease, stroke, high blood pressure, diabetes, allergy to chamomile, severe PPD, or those who were under medication for their depression were excluded from the study.

3.3. Randomization, Allocation Concealment and Blinding

A block randomization method with a block size of six and an allocation ratio of 1:1 was used for randomization. The codes were kept in sealed opaque envelopes until the time of intervention. Therefore, neither the researchers nor the participants were aware of group allocation. This was a double-blind randomized study, as the coding of chamomile capsules and the placebo was done by the pharmacist, and both the researchers and the participants were unaware of the content of the drug containers.

3.4. Setting

The postpartum women were screened and recruited from four public health centers in Dezful, Iran (No 1, 4, 2, and Teacher’s Health center).

3.5. Instruments

A demographic questionnaire and Beck's Depression Inventory (BDI-II) were used to collect the data. The demographic questionnaire contained questions about age, education, occupation, economic status, mode of delivery, intention for pregnancy, husband's age, educational attainment, and occupation. The content validity of this questionnaire was confirmed by five faculty members.

Developed by Aaron Beck, BDI-II is a 21-item multiple-choice questionnaire that measures the severity of depression. BDI-II assesses the participant's feelings over the past week. Each question is scored from 0 (indicating no sad feelings) to 3 (indicating unbearable sad feelings). The cut-off points for this questionnaire are as follows: 0 - 9 indicating minimal depression, 10 - 18 indicating mild depression, 19 - 29 indicating moderate depression, and 30 - 63 indicating severe depression (18). The psychometric properties of this questionnaire were evaluated by Toosi et al. in Iran (19).

3.6. Intervention

The chamomile and placebo capsules were purchased from Adonis Gol Daru, Iran. The medications were kept in identical containers. Participants received chamomile or placebo (500 mg) twice a day for eight weeks. This dose was selected according to two previous studies (11-20). Women with mild to moderate depression, as determined by the BDI, were randomized into intervention and control groups. They were requested to complete the demographic and BDI questionnaires before and eight weeks after the intervention.

One of the researchers (ME) was accessible in case participants had any questions during the eight weeks of the intervention. To abide by ethical standards, after the completion of the intervention, participants in the control group were instructed on how to use chamomile if they were interested in using it.

3.7. Statistics

All data were imported into SPSS version 26. The normality of the data was assessed using the Shapiro-Wilk test. The chi-square test and independent t-test were used to compare categorical and numerical data between the two groups. For non-parametric variables, the Mann-Whitney U test was used, and the Wilcoxon test was used to compare the frequency of depression between the two groups. P-values less than 0.05 were considered statistically significant.

4. Results

In this study, 144 postpartum women with mild to moderate depression were recruited. Six women in the intervention group and four in the control group withdrew from the study, resulting in 128 women who completed the study. The reasons for dropouts are presented in Figure 1. The mean age of women in the intervention and control groups was 30.50 ± 5.26 years and 31.32 ± 7.05 years, respectively. The mean body mass index of the two groups indicated that women in both groups were overweight. There were no significant differences between the two groups regarding women’s educational attainment, husbands’ educational attainment, economic status, and occupation. Most women in both groups delivered their babies vaginally [intervention: 44 (69.8%); control: 48 (73.8%)] (Table 1).

CONSORT flow-diagram of study
CONSORT flow-diagram of study
Figure 1.

CONSORT flow-diagram of study

Table 1.

Demographic and Obstetrics Characteristics of the Participants in Intervention and Control Groups a

Variables Intervention (N = 63)Control (N = 65)P-Value
Age (y)30.50 ± 5.2631.32 ± 7.050.793
Body Mass Index (kg/m2)30.77 ± 8.6231.81 ± 9.420.512
Age of husband (y)33.85 ± 5.6834.10 ± 7.080.897
Educational attainment 0.722
Diploma and high school14 (22.2)18 (27.7)
Associate degree 37 (58.7)37 (56.9)
Bachelor’s degree 12 (19)10 (15.4)
Educational attainment of husband 0.761
Diploma and high school19 (30.2)23 (35.4)
Associate degree 29 (46)26 (40)
Bachelor’s degree 15 (23.8)16 (24.6)
Occupation 0.922
Housewife 48 (76.2)50 (76.9)
Employed 15 (23.8)15 (23.1)
Do your income cover your expenses 0.226
No 23 (36.5)29 (44.6)
Somehow 29 (46)31 (47.7)
Yes 11 (17.5)5 (7.7)
Was your pregnancy intended? 0.614
Yes 58 (92.1)61 (93.8)
No 5 (7.9)4 (6.2)
Mode of delivery 0.614
Normal vaginal delivery44 (69.8)48 (73.8)
Cesarean 19 (30.2)17 (26.2)

a Values are expressed as No. (%) or mean ± SD.

Table 2 shows the comparison of the mean depression scores and their frequency before and after the intervention. The mean depression score in the intervention group was 21.66 ± 4.01 at baseline, which reduced to 18 ± 3.66 after the intervention. In the control group, the depression scores decreased from 22.36 ± 3.83 at baseline to 20.09 ± 3.77 after the intervention. The within-group differences were significant in both groups (P < 0.0001). The reduction in depression score was statistically significant in the intervention group compared to the control group (P = 0.002).

Before the intervention, 41 (65.1%) women in the intervention group and 50 (76.9%) women in the control group had moderate depression. After the intervention, 7 (11.1%) women in the intervention group were without depression, and 60.3% had mild depression, while the reduction was negligible in the control group (P = 0.002).

Table 2.

Comparison of Mean Score and Frequency of Depression in the Intervention and Control Groups a

Variables Intervention (N = 63)Control (N = 65)P-Value b
Depression score before intervention 21.66 ± 4.0122.36 ± 3.830.253
Depression score after intervention 18 ± 3.6620.09 ± 3.770.002
P-Value c< 0.0001< 0.0001
Before intervention P-Value
No depression 000.139 c
Mild depression22 (34.9)15 (23.1)
Moderate depression 41 (65.1)50 (76.9)
After intervention 0.002
No depression 7 (11.1)2 (3.1)
Mild depression38 (60.3)25 (38.5)
Moderate depression 18 (28.6)38 (58.5)

a Values are expressed as No. (%) or mean ± SD.

b Mann-Whitney U test.

c Wilcoxon test.

5. Discussion

This study was designed to evaluate the effect of chamomile on PPD. The pathogenesis of depression mostly relies on the reduction of serotonin and tryptophan, which can induce depressive symptoms (21). In postpartum women, the rapid reduction of estrogen and progesterone hormones after birth is considered an etiology of PPD. These hormones play an important role in preserving emotion, arousal, condition, and motivation (22).

The results of the present study showed that chamomile could significantly reduce the mean score and frequency of PPD. The mechanism by which chamomile reduces depression may result from its anti-inflammatory and antioxidant activities, modulated by macrophages and CD4 T cells. Therefore, the immune response of people with depression may improve after the consumption of its extract or oil (23). In a study on rats, Juhas et al. found that dietary supplementation of 5000 ppm of chamomile not only significantly reduced edema and weight in the animals but also had protective effects on colonic mucosa and signs of Trinitrobenzene Sulfonic Acid (TNBS)-induced colonic inflammation (24).

Despite a few studies evaluating the effect of chamomile on anxiety and depression in general (11), there is a paucity of research specifically assessing its effect on PPD. The only similar study we found was conducted by Chang and Chen with the participation of 80 postpartum women suffering from poor sleep quality. These women were assigned to a chamomile tea group (for two weeks) and a control group. Sleep quality and symptoms of depression improved significantly in the intervention group, although these effects were immediate and did not last after the post-test. Our results are consistent with those of Chang and Chen, except we used chamomile capsules (500 mg twice a day for eight weeks), which may have improved the efficacy of the intervention.

In another study conducted on 120 patients with depressive disorders, Ahmad et al. found that using a herbal tea including chamomile (20 mg) and saffron (1 mg) twice a day for four weeks significantly improved patient health and depression scores, and reduced inflammatory markers such as C-Reactive Protein (CRP) and Tryptophan (TRP) in the plasma, resulting in an increase of TRP in the brain (21). Although this study was not on postpartum women, it supports our findings.

Heidari-Fard et al. found that chamomile aromatherapy during labor significantly increased satisfaction with birth but was not effective regarding uterus contractions (25). Amsterdam et al. studied 57 participants with co-morbid anxiety and depression and found that chamomile significantly reduced depression scores, with a non-significant reduction in participants who had anxiety and co-morbid depression (26).

Bazrafshan et al. compared the effect of 2 g of lavender with chamomile on anxiety and depression in postmenopausal women. Their results showed that both herbs significantly reduced anxiety and depression scores (13). Our results are consistent with the findings of Amsterdam et al. and Bazrafshan et al. (13, 26).

5.1. Limitations

Despite its merits, this study has some limitations. First, the women were recruited from four public health centers in Dezful, Iran, which may limit the generalizability of the findings. Second, we recruited women with mild and moderate PPD; therefore, the effect of chamomile on severe PPD remains to be evaluated in future studies. Third, participants in the intervention group consumed chamomile for eight weeks and were then assessed for depression. We are uncertain about the durability of the drug's effects beyond eight weeks. Further studies with longer follow-up periods are recommended to shed more light on this issue.

5.2. Conclusions

The results of the present study showed that chamomile capsules (500 mg) consumed twice a day for eight weeks significantly reduced the score and frequency of mild and moderate PPD. Due to the lack of laboratory evaluation, these results should be interpreted with caution, and further studies are needed to confirm these findings.

Acknowledgements

References

  • 1.

    Skalkidou A, Hellgren C, Comasco E, Sylven S, Sundstrom Poromaa I. Biological aspects of postpartum depression. Womens Health (Lond). 2012;8(6):659-72. [PubMed ID: 23181531]. https://doi.org/10.2217/whe.12.55.

  • 2.

    Getahun D, Oyelese Y, Peltier M, Yeh M, Chiu VY, Takhar H, et al. Trends in Postpartum Depression by Race/Ethnicity and Pre-pregnancy Body Mass Index. Am J Obstet Gynecol. 2023;228(1):S122-3. https://doi.org/10.1016/j.ajog.2022.11.248.

  • 3.

    Afshari P, Tadayon M, Abedi P, Yazdizadeh S. Prevalence and related factors of postpartum depression among reproductive aged women in Ahvaz, Iran. Health Care Women Int. 2020;41(3):255-65. [PubMed ID: 30924721]. https://doi.org/10.1080/07399332.2019.1578779.

  • 4.

    Afshari P, Tadayon M, Abedi P, Beheshtinasab M. Comparison of pre-and intra-COVID-19 postpartum depression among reproductive aged women: A comparative cross-sectional study in Ahvaz, Iran. Frontiers Psychiatry. 2022;13:1019432. [PubMed ID: 36424994]. [PubMed Central ID: PMC9679291].

  • 5.

    Slomian J, Honvo G, Emonts P, Reginster JY, Bruyere O. Consequences of maternal postpartum depression: A systematic review of maternal and infant outcomes. Womens Health (Lond). 2019;15:1745506519844040. [PubMed ID: 31035856]. [PubMed Central ID: PMC6492376]. https://doi.org/10.1177/1745506519844044.

  • 6.

    No authors listed. Maternal depression and child development. Paediatr Child Health. 2004;9(8):575-98. [PubMed ID: 19680490]. [PubMed Central ID: PMC2724169]. https://doi.org/10.1093/pch/9.8.575.

  • 7.

    Kimmel MC, Cox E, Schiller C, Gettes E, Meltzer-Brody S. Pharmacologic Treatment of Perinatal Depression. Obstet Gynecol Clin North Am. 2018;45(3):419-40. [PubMed ID: 30092919]. https://doi.org/10.1016/j.ogc.2018.04.007.

  • 8.

    Dimidjian S, Goodman S. Nonpharmacologic intervention and prevention strategies for depression during pregnancy and the postpartum. Clin Obstet Gynecol. 2009;52(3):498-515. [PubMed ID: 19661764]. [PubMed Central ID: PMC5805470]. https://doi.org/10.1097/GRF.0b013e3181b52da6.

  • 9.

    Babakhanian M, Rashidi Fakari F, Mortezaee M, Bagheri Khaboushan E, Rahimi R, Khalili Z, et al. The Effect of Herbal Medicines on Postpartum Depression, and Maternal-Infant Attachment in Postpartum Mother: A Systematic Review and Meta-Analysis. Int J Pediatr. 2019;7(7):9645-56.

  • 10.

    Srivastava JK, Shankar E, Gupta S. Chamomile: A herbal medicine of the past with bright future. Mol Med Rep. 2010;3(6):895-901. [PubMed ID: 21132119]. [PubMed Central ID: PMC2995283]. https://doi.org/10.3892/mmr.2010.377.

  • 11.

    Amsterdam JD, Li QS, Xie SX, Mao JJ. Putative Antidepressant Effect of Chamomile (Matricaria chamomilla L.) Oral Extract in Subjects with Comorbid Generalized Anxiety Disorder and Depression. J Altern Complement Med. 2020;26(9):813-9. [PubMed ID: 31808709]. [PubMed Central ID: PMC7488203]. https://doi.org/10.1089/acm.2019.0252.

  • 12.

    Chang SM, Chen CH. Effects of an intervention with drinking chamomile tea on sleep quality and depression in sleep disturbed postnatal women: a randomized controlled trial. J Adv Nurs. 2016;72(2):306-15. [PubMed ID: 26483209]. https://doi.org/10.1111/jan.12836.

  • 13.

    Bazrafshan M, Masmouei B, Soufi O, Delam H. Comparison of the Effectiveness of Lavender and Chamomile Herbal Tea on Anxiety and Depression in Postmenopausal Women: a Randomized Controlled Trial. Women’s Health Bulletin. 2022;9(3):172-80. https://doi.org/10.30476/whb.2022.94844.1172.

  • 14.

    Lee SH, Heo Y, Kim YC. Effect of German chamomile oil application on alleviating atopic dermatitis-like immune alterations in mice. J Vet Sci. 2010;11(1):35-41. [PubMed ID: 20195063]. [PubMed Central ID: PMC2833428]. https://doi.org/10.4142/jvs.2010.11.1.35.

  • 15.

    Menghini L, Ferrante C, Leporini L, Recinella L, Chiavaroli A, Leone S, et al. An Hydroalcoholic Chamomile Extract Modulates Inflammatory and Immune Response in HT29 Cells and Isolated Rat Colon. Phytother Res. 2016;30(9):1513-8. [PubMed ID: 27237110]. https://doi.org/10.1002/ptr.5655.

  • 16.

    Wang W, Yue RF, Jin Z, He LM, Shen R, Du D, et al. Efficiency comparison of apigenin-7-O-glucoside and trolox in antioxidative stress and anti-inflammatory properties. J Pharm Pharmacol. 2020;72(11):1645-56. [PubMed ID: 32743812]. https://doi.org/10.1111/jphp.13347.

  • 17.

    Chandrashekhar VM, Halagali KS, Nidavani RB, Shalavadi MH, Biradar BS, Biswas D, et al. Anti-allergic activity of German chamomile (Matricaria recutita L.) in mast cell mediated allergy model. J Ethnopharmacol. 2011;137(1):336-40. [PubMed ID: 21651969]. https://doi.org/10.1016/j.jep.2011.05.029.

  • 18.

    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-71. [PubMed ID: 13688369]. https://doi.org/10.1001/archpsyc.1961.01710120031004.

  • 19.

    Toosi F, Rahimi C, Sajjadi S. Psychometric Properties of Beck Depression Inventory-II for High School Children in Shiraz City, Iran. Int J Sch Health. 2017;In press(In press). https://doi.org/10.5812/intjsh.41069.

  • 20.

    Mao JJ, Xie SX, Keefe JR, Soeller I, Li QS, Amsterdam JD. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine. 2016;23(14):1735-42. [PubMed ID: 27912875]. [PubMed Central ID: PMC5646235]. https://doi.org/10.1016/j.phymed.2016.10.012.

  • 21.

    Ahmad S, Azhar A, Tikmani P, Rafique H, Khan A, Mesiya H, et al. A randomized clinical trial to test efficacy of chamomile and saffron for neuroprotective and anti-inflammatory responses in depressive patients. Heliyon. 2022;8(10). e10774. [PubMed ID: 36217471]. [PubMed Central ID: PMC9547202]. https://doi.org/10.1016/j.heliyon.2022.e10774.

  • 22.

    Schiller CE, Meltzer-Brody S, Rubinow DR. The role of reproductive hormones in postpartum depression. CNS Spectr. 2015;20(1):48-59. [PubMed ID: 25263255]. [PubMed Central ID: PMC4363269]. https://doi.org/10.1017/S1092852914000480.

  • 23.

    De Cicco P, Ercolano G, Sirignano C, Rubino V, Rigano D, Ianaro A, et al. Chamomile essential oils exert anti-inflammatory effects involving human and murine macrophages: Evidence to support a therapeutic action. J Ethnopharmacol. 2023;311:116391. [PubMed ID: 36948263]. https://doi.org/10.1016/j.jep.2023.116391.

  • 24.

    Juhás Š, Bukovská A, Čikoš Š, Czikková S, Fabian D, Koppel J. Anti-Inflammatory Effects of Rosmarinus officinalis Essential Oil in Mice. Acta Veterinaria Brno. 2009;78(1):121-7. https://doi.org/10.2754/avb200978010121.

  • 25.

    Heidari-Fard S, Mohammadi M, Fallah S. The effect of chamomile odor on contractions of the first stage of delivery in primpara women: A clinical trial. Complement Ther Clin Pract. 2018;32:61-4. [PubMed ID: 30057060]. https://doi.org/10.1016/j.ctcp.2018.04.009.

  • 26.

    Amsterdam JD, Shults J, Soeller I, Mao JJ, Rockwell K, Newberg AB. Chamomile (Matricaria recutita) may provide antidepressant activity in anxious, depressed humans: an exploratory study. Altern Ther Health Med. 2012;18(5):44-9. [PubMed ID: 22894890]. [PubMed Central ID: PMC3600408].